Epcoritamab

Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3xCD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines[1].

Product Specifications

CAS Number

[2134641-34-0]

Product Name Alternative

GEN3013

UNSPSC

12352203

Target

CD20; CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/epcoritamab.html

Purity

99.84

Solubility

10 mM in DMSO

Smiles

[Epcoritamab]

Molecular Weight

(146.28 kDa)

References & Citations

[1]van der Horst HJ, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021 Feb 18;11 (2) :38. |[2]Thieblemont C, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41 (12) :2238-2247.